Recent performance and what has caught investors’ attention

Reinsurance Group of America (RGA) has drawn fresh interest after recent share price moves, with the stock ending the latest session at US$201.21 and sitting slightly down year to date.

Short term returns have been mixed, with the stock down about 2% over the past week, down roughly 4% over the past month, and lower by around 3% over the past 3 months, while the 1 year total return is slightly positive.

Putting this into context, RGA’s recent share price has eased slightly over the past month, yet its 3 year total shareholder return of 48.13% and 5 year total shareholder return of 81.33% show a materially stronger longer term record.

If this kind of multi year compounding interests you, it may be worth widening your search to see which other companies make it into our 20 top founder-led companies

So with RGA’s share price treading water while longer term returns remain solid and analyst targets sit higher, is the stock quietly undervalued here, or has the market already priced in its future growth?

Most Popular Narrative: 19% Undervalued

The most followed narrative currently pegs Reinsurance Group of America’s fair value at about $248, compared with the last close of $201.21. This implies a meaningful gap that hinges on a specific set of growth and profitability assumptions.

RGA is capitalizing on growing insurance demand in Asia and other international markets, as evidenced by robust new business in Hong Kong, Taiwan, Korea, and a record number of asset-intensive transactions across five countries and three continents; this global expansion drives sustained premium growth and strengthens revenue diversification.

The company's leadership in digital underwriting solutions and customized reinsurance products, bolstered by data analytics and exclusive arrangements, enhances efficiency and pricing power, which is likely to improve net margins and generate higher earnings as these tech-enabled capabilities scale.

Curious what is baked into that valuation gap? The narrative leans on steady revenue expansion, firmer margins and a lower future earnings multiple than many peers. The full set of assumptions may surprise you.

Result: Fair Value of $248.44 (UNDERVALUED)

However, there are still pressure points to watch, including earnings swings from U.S. life and healthcare excess claims, as well as the risk that rising medical costs compress future margins.

Next Steps

With mixed signals across returns and valuation assumptions, it makes sense to look past the headline narrative, act quickly and test the numbers yourself by reviewing the 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you risk missing other clear opportunities, so broaden your watchlist now and keep your capital working harder across the market.

• Target value by scanning companies that combine quality fundamentals with attractive pricing using the 47 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses that show stronger balance sheets and healthier fundamentals through the solid balance sheet and fundamentals stocks screener (46 results).
• Spot tomorrow’s potential standouts early by reviewing the screener containing 21 high quality undiscovered gems before they are widely talked about.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.